Sugi Predict

Sugi Predict / Compounds / SCHEMBL5064624

SCHEMBL5064624

SCHEMBL5064624

COc1ccccc1-c1cn(S(=O)(=O)c2ccc(C)cc2)c2ncc(-c3cccc(C(O)c4ncccc4C(F)(F)F)c3)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN11 Q06124 2/20 0.38
▸ MAPT P10636 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ TSHR P16473 1/20 0.36
▸ MAOB P27338 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ HSD11B1 P28845 1/20 0.34
▸ SLC1A3 P43003 1/20 0.32
▸ SLC1A2 P43004 1/20 0.32
▸ SLC1A1 P43005 1/20 0.32
▸ SCN9A Q15858 2/20 0.32
▸ SCN5A Q14524 1/20 0.32
▸ PDE4B Q07343 1/20 0.32
▸ NR1H2 P55055 1/20 0.32
▸ EED O75530 2/20 0.32
▸ APLNR P35414 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ HTR2A P28223 1/20 0.32
▸ HTR2C P28335 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11968504 0.86 PTPN11 (0.41) PTPN11MAPTSMN1; SMN2TSHRMAOB
SCHEMBL11968476 0.83 PTPN11 (0.40) PTPN11MAPTSMN1; SMN2TSHRL3MBTL1
SCHEMBL5060870 0.83 PTPN11 (0.46) PTPN11MAPTSMN1; SMN2TSHRSLC1A3
SCHEMBL11968665 0.81 PTPN11 (0.43) PTPN11MAPTSMN1; SMN2TSHRSLC1A3
SCHEMBL1516771 0.77 PTPN11 (0.46) PTPN11MAPTSMN1; SMN2TSHRL3MBTL1
SCHEMBL4360033 0.77 PTPN11 (0.41) PTPN11MAPTSMN1; SMN2TSHRSLC1A3
SCHEMBL5067371 0.77 PTPN11 (0.46) PTPN11MAPTSMN1; SMN2TSHRSLC1A3
SCHEMBL5067365 0.76 ABL1 (0.48) —
SCHEMBL1516754 0.76 PTPN11 (0.43) PTPN11MAPTSMN1; SMN2TSHRSCN9A
SCHEMBL1516635 0.76 PTPN11 (0.46) PTPN11MAPTSMN1; SMN2TSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242280-B2 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia SGX PHARMACEUTICALS, INC. (US) 2012-08-14 — — US disclosed
US-8242280-B2 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia SGX PHARMACEUTICALS, INC. (US) 2012-08-14 — — US disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, MAP3K19, MAP4K2 PTPN11 886/4885MAPT 2466/4885SMN1; SMN2 3542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.